MX364690B - Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero. - Google Patents

Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero.

Info

Publication number
MX364690B
MX364690B MX2015012450A MX2015012450A MX364690B MX 364690 B MX364690 B MX 364690B MX 2015012450 A MX2015012450 A MX 2015012450A MX 2015012450 A MX2015012450 A MX 2015012450A MX 364690 B MX364690 B MX 364690B
Authority
MX
Mexico
Prior art keywords
serum
manufacturing process
cell culture
culture system
lentiviral vectors
Prior art date
Application number
MX2015012450A
Other languages
English (en)
Other versions
MX2015012450A (es
Inventor
Qu Guang
Fraser Wright John
Original Assignee
Childrens Hospital Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Philadelphia filed Critical Childrens Hospital Philadelphia
Publication of MX2015012450A publication Critical patent/MX2015012450A/es
Publication of MX364690B publication Critical patent/MX364690B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Manufacturing & Machinery (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para preparar formulaciones de vectores rLV altamente purificadas a la escala necesaria para satisfacer la demanda anticipada para terapia génica humana.
MX2015012450A 2013-03-15 2014-03-17 Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero. MX364690B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361787818P 2013-03-15 2013-03-15
PCT/US2014/030370 WO2014145578A1 (en) 2013-03-15 2014-03-17 Scalable manufacturing process to produce recombinant lentiviral vectors in serum-free suspension cell culture system

Publications (2)

Publication Number Publication Date
MX2015012450A MX2015012450A (es) 2016-04-25
MX364690B true MX364690B (es) 2019-05-06

Family

ID=51538029

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012450A MX364690B (es) 2013-03-15 2014-03-17 Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero.

Country Status (17)

Country Link
US (2) US20140323556A1 (es)
EP (1) EP2970920B1 (es)
JP (1) JP6480910B6 (es)
KR (1) KR102200278B1 (es)
CN (2) CN118256453A (es)
AU (1) AU2014232879B2 (es)
BR (1) BR112015022292A2 (es)
CA (1) CA2904366C (es)
DK (1) DK2970920T3 (es)
ES (1) ES2681434T3 (es)
HK (1) HK1219978A1 (es)
IL (1) IL241058B (es)
MX (1) MX364690B (es)
PT (1) PT2970920T (es)
RU (1) RU2709678C2 (es)
WO (1) WO2014145578A1 (es)
ZA (1) ZA201506478B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
IL284985B2 (en) 2015-02-18 2023-03-01 Enlivex Therapeutics R& D Ltd Combined immunotherapy and cytokine control therapy for cancer treatment
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
TWI547782B (zh) * 2015-03-16 2016-09-01 智易科技股份有限公司 可擴充式製程系統與實現該系統的方法
EP3285877B1 (en) 2015-04-21 2022-10-19 Enlivex Therapeutics Rdo Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
EP3384015A4 (en) * 2015-12-01 2019-05-29 Spark Therapeutics, Inc. SCALABLE PROCESS FOR THE PREPARATION OF A RECOMBINANT ADENO ASSOCIATED VIRAL VECTOR IN A SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR THE CLINICAL APPLICATION
CN107043784A (zh) * 2016-02-05 2017-08-15 上海吉凯基因化学技术有限公司 一种慢病毒载体的制备方法
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
EP3436576A4 (en) * 2016-03-30 2019-10-30 Spark Therapeutics, Inc. CELL LINE FOR THE PRODUCTION OF RECOMBINANT PROTEIN AND / OR A RECOMBINANT VIRAL VECTOR
US10358626B2 (en) 2016-04-12 2019-07-23 Artemis Biosystems, Inc. Perfusion filtration systems
CN106497882A (zh) * 2016-10-29 2017-03-15 复旦大学 同时过表达R‑spondin1和Noggin的细胞株及其构建方法和应用
ES2975182T3 (es) 2017-03-06 2024-07-03 Guangzhou Realbenefitspot Pharmaceutical Co Ltd Métodos de producción y caracterización de vacunas víricas y composición de vacuna vírica
EP3420076B1 (en) 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
CN109251939A (zh) * 2017-07-14 2019-01-22 孙搏 Il-17g-197a慢病毒表达载体、其构建方法及慢病毒的包装测定方法
KR102074336B1 (ko) * 2018-01-24 2020-02-06 주식회사 에스엘바이젠 뇌유래-신경영양인자를 발현하는 중간엽줄기세포주 및 이의 용도
CN111763238B (zh) * 2019-04-02 2022-07-29 普莱柯生物工程股份有限公司 一种蛋白抗原的纯化方法、制备的蛋白抗原及其应用
HUE064411T2 (hu) * 2019-04-11 2024-03-28 Regenxbio Inc Méretkizárásos kromatográfiás módszerek rekombináns adeno-asszociált víruskészítmények jellemzésére
CN110054678B (zh) * 2019-05-16 2023-04-18 中国医学科学院血液病医院（血液学研究所） 一种膜结合型mFLT3LG蛋白及其应用
KR20220047635A (ko) 2019-08-23 2022-04-18 론자 워커스빌 아이엔씨. 렌티바이러스 벡터의 생산을 위한 방법 및 작제물
CN110894494B (zh) * 2019-11-22 2022-09-27 广西梧州制药（集团）股份有限公司 一种大规模高密度悬浮培养293细胞高产腺病毒的方法
CN110938654A (zh) * 2019-12-11 2020-03-31 和元生物技术（上海）股份有限公司 一种细胞转染试剂及其应用
CN113122501B (zh) * 2019-12-30 2023-06-16 重庆精准生物技术有限公司 适合大规模临床级病毒载体制备的培养基及其应用
EP4196596A1 (en) * 2020-08-13 2023-06-21 Tmunity Therapeutics Inc. Methods for producing clinical-grade lentiviral vector
CN112746076B (zh) * 2020-12-28 2023-05-12 中吉智药(南京)生物技术有限公司 一种密码子优化的col7a1基因及慢病毒和应用
US20240101964A1 (en) * 2020-12-29 2024-03-28 Jiangsu Genscript Probio Biotech Co., Ltd. Hek293t cell strain having high dispersibility and screening method therefor
JP2024526850A (ja) * 2021-07-19 2024-07-19 ２セブンティ バイオ インコーポレイテッド ベクター製造方法
CN113980916A (zh) * 2021-09-27 2022-01-28 湖南丰晖生物科技有限公司 一种慢病毒的纯化方法
WO2023061409A1 (zh) * 2021-10-12 2023-04-20 江苏金斯瑞蓬勃生物科技有限公司 适应无血清悬浮培养的hek293细胞株及其应用
CN114990077A (zh) * 2022-08-01 2022-09-02 深圳市先康达生命科学有限公司 一种慢病毒包装与纯化方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US20030157070A1 (en) * 1994-12-30 2003-08-21 Jolly Douglas J. High efficiency ex vivo transduction of cells by high titer recombinant retroviral preparations
US6544769B1 (en) * 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6207455B1 (en) 1997-05-01 2001-03-27 Lung-Ji Chang Lentiviral vectors
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US7575924B2 (en) * 2000-11-13 2009-08-18 Research Development Foundation Methods and compositions relating to improved lentiviral vectors and their applications
WO2003039459A2 (en) * 2001-11-05 2003-05-15 Genvec, Inc. Viral vector production methods and compositions
BR0309659A (pt) * 2002-04-30 2005-02-22 Oncolytics Biotech Inc Método para produzir vìrus de uma cultura de células, composição, e, método para produzir reovìrus infeccioso
AU2003272868A1 (en) * 2003-10-15 2005-04-27 Agtc Gene Technology Company Ltd. Method for large-scale production, isolation, purification and the uses of multi-type recombinant adeno-associated virus vectors
KR101326438B1 (ko) * 2005-07-06 2013-11-07 지이 헬스케어 바이오-사이언시스 에이비 분리 매트릭스의 제조 방법
CN101314775B (zh) * 2007-05-31 2013-02-06 厦门大学 可用于艾滋病治疗的rna干扰靶点
EP2012122A1 (en) * 2007-07-06 2009-01-07 Medigene AG Mutated parvovirus structural proteins as vaccines
DK3192874T3 (da) * 2008-06-18 2019-12-16 Oxford Biomedica Ltd Virusoprensning
CN103952376A (zh) * 2008-09-24 2014-07-30 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
KR101812813B1 (ko) 2009-06-16 2017-12-27 젠자임 코포레이션 재조합 ａａｖ 벡터에 대한 개선된 정제 방법
SG182490A1 (en) * 2010-01-12 2012-08-30 Vascular Biogenics Ltd Methods of producing adenovirus vectors and viral preparations generated thereby
WO2011097447A2 (en) * 2010-02-04 2011-08-11 Neurologix, Inc. Production of recombinant virus

Also Published As

Publication number Publication date
JP6480910B2 (ja) 2019-03-13
US10994028B2 (en) 2021-05-04
US20140323556A1 (en) 2014-10-30
IL241058B (en) 2020-05-31
AU2014232879A1 (en) 2015-09-24
MX2015012450A (es) 2016-04-25
CA2904366A1 (en) 2014-09-18
JP2016512700A (ja) 2016-05-09
RU2709678C2 (ru) 2019-12-19
ZA201506478B (en) 2021-09-29
EP2970920B1 (en) 2018-04-25
KR20160024841A (ko) 2016-03-07
PT2970920T (pt) 2018-07-30
RU2015144057A (ru) 2017-04-27
CN118256453A (zh) 2024-06-28
JP6480910B6 (ja) 2019-04-03
HK1219978A1 (zh) 2017-04-21
CA2904366C (en) 2023-07-04
ES2681434T3 (es) 2018-09-13
EP2970920A1 (en) 2016-01-20
US20170368201A1 (en) 2017-12-28
EP2970920A4 (en) 2016-09-14
CN105378074A (zh) 2016-03-02
BR112015022292A2 (pt) 2017-07-18
KR102200278B1 (ko) 2021-01-07
WO2014145578A1 (en) 2014-09-18
DK2970920T3 (en) 2018-08-06
AU2014232879B2 (en) 2020-03-05
IL241058A0 (en) 2015-11-30

Similar Documents

Publication Publication Date Title
MX364690B (es) Proceso de elaboracion escalable para producir vectores lentivirales recombinantes en un sistema de cultivo celular en suspension libre de suero.
IL259595A (en) Gradual methods for the production of a recombinant adenovirus (aav) vector in a serum-free suspension cell culture system suitable for clinical use
PH12015500284A1 (en) Interleukin-10 fusion proteins and uses thereof
PH12014502767A1 (en) Interleukin-2 fusion proteins and uses thereof
MX340102B (es) Una plataforma de fabricacion ajustable en escala, para la purificacion de vector viral y vectores virales asi purificados para el uso en terapia de genes.
MY166059A (en) Fusion Proteins for Treating Metabolic Disorders
MY173953A (en) Recombinant host cells for the production of malonate
MX2020010991A (es) Composicion para la estimulacion ovarica controlada.
MX360779B (es) Composiciones de cultivo celular con antioxidantes y métodos para la producción de polipéptidos.
WO2012031263A3 (en) Cell culture system for bioreactor scale-up of cells
WO2012068317A3 (en) Methods for producing recombinant proteins
HK1200848A1 (en) Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
EP2935581A4 (en) EXPRESSION VECTORS FOR THE PRODUCTION OF RECOMBINANT PROTEINS IN MAMMALIAN CELLS
HK1250743A1 (zh) 表達載體組織、新的生產用細胞產生方法及其在重組產生多肽中的用途
IN2014CN03414A (es)
GB201122408D0 (en) Method for preparing dry protein formulations
NZ729729A (en) Production of fully processed and functional factor x in a furin-secreting mammalian expression system
IN2013MU02526A (es)
MX2020002551A (es) Metodos, composiciones y celulas para preparar proteina surfactante d (sp-d).
HK1221977A1 (zh) 用於產生供生產重組蛋白的哺乳動物生產細胞的物品和方法
HK1203360A1 (en) Large commercial scale lentiviral vector production system and vectors produced thereby

Legal Events

Date Code Title Description
FG Grant or registration